Sign in

John Houston

President and Chief Executive Officer at ARVINAS
Board
Since September 2017
Age
65 years
Education
Holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh, and a B.Sc. in medical microbiology from the University of Glasgow.
Tenure
Joined ARVN in September 2017 as President and Chief Executive Officer, serving in additional roles such as President of Research and Development, Chief Scientific Officer, and Principal Executive Officer, and was promoted to Chairperson in June 2023.

Also at ARVINAS

AS
Andrew Saik
Chief Financial Officer, Treasurer, and Principal Financial Officer
AC
Angela Cacace
Chief Scientific Officer
IT
Ian Taylor
President of Research and Development

About

John Houston, Ph.D., has a robust academic foundation with advanced degrees in microbial biochemistry and medical microbiology, which have equipped him with deep scientific expertise.

With extensive experience in the pharmaceutical and biotechnology sectors, he held senior roles at organizations including Bristol-Myers Squibb and Glaxo Wellcome Research and Development, contributing to innovative research and discovery.

At ARVN, he has played a pivotal leadership role since September 2017 as President and Chief Executive Officer, undertaking additional responsibilities as President of Research and Development, Chief Scientific Officer, and Principal Executive Officer, and later being promoted to Chairperson in June 2023.

$ARVN Performance Under John Houston

Past Roles

OrganizationRoleDate RangeDetails
Arvinas (ARVN) President of Research and Development January 2017 - June 2024 Former role prior to CEO appointment
Arvinas (ARVN) Chief Scientific Officer January 2017 - April 2019 Former role
Arvinas (ARVN) Principal Executive Officer Since February 2017 Former role
Bristol-Myers Squibb Senior Vice President, Head of Specialty Discovery September 2015 - August 2016 Former role
Bristol-Myers Squibb Senior Vice President of Disease Sciences, Biologics and Applied Biotechnology August 2008 - September 2015 Former role
Glaxo Wellcome R&D (UK) Head of the Lead Discovery Unit N/A Former role

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Base Salary $684,0052024 (annual)Guaranteed base salary for 2024
401(k) Matching Contributions $13,8002024 (as earned)401(k) match provided during 2024
Stock Awards (RSUs) $11,622,357 (grant fair value)<br>124,450 RSUsGrant Date: February 23, 2024Grant Date Stock Price: $47.00 per share; Vesting details not explicitly provided
Option Awards 184,200 optionsGrant Date: February 23, 2024;<br>50% vest on February 23, 2025, 50% vest on February 23, 2026Exercise Price: $47.00 per share; Grant Date Fair Value: $11,622,357

Performance Compensation

Data from  FY 2024

Non-Equity Incentive Plan Compensation

MetricValueAdditional Details
Bonus Target Percentage 60% of base salaryBonus tied solely to achievement of corporate goals; no thresholds or caps specified
Actual Payout Amount $426,819Earned in 2024 and paid in 2025
Payment Timing Earned in 2024, paid in 2025Cash-based bonus program without vesting requirements
Performance Conditions Achievement of corporate goalsNo additional performance metrics, thresholds, caps, or weighted targets provided